董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Ali J. Satvat | 男 | Director | 41 | 未披露 | 未持股 | 2019-03-31 |
| Eric Aguiar | 男 | Director | 56 | 未披露 | 未持股 | 2019-03-31 |
| Charles Homcy | 男 | Chairman of Pharmaceuticals, Director | 70 | 20.00万美元 | 未持股 | 2019-03-31 |
| Neil Kumar | 男 | Chief Executive Officer, Director | 40 | 45.00万美元 | 未持股 | 2019-03-31 |
| Richard H. Scheller | 男 | Chairman of Research & Development, Director | 65 | 10.00万美元 | 未持股 | 2019-03-31 |
| James C. Momtazee | 男 | Director | 47 | 未披露 | 未持股 | 2019-03-31 |
| Frank McCormick | 男 | Chairman of Oncology | 68 | 未披露 | 未持股 | 2019-03-31 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Neil Kumar | 男 | Chief Executive Officer, Director | 40 | 45.00万美元 | 未持股 | 2019-03-31 |
| Uma Sinha | 女 | Chief Scientific Officer | 62 | 275.09万美元 | 未持股 | 2019-03-31 |
| Brian C. Stephenson | 男 | Chief Financial Officer | 38 | 234.71万美元 | 未持股 | 2019-03-31 |
| Cameron Turtle | 男 | Senior Vice President, Portfolio Management and Corporate Development | 29 | 未披露 | 未持股 | 2019-03-31 |
| Michael Henderson | 男 | Senior Vice President, Asset Acquisition, Strategy and Operations | 30 | 未披露 | 未持股 | 2019-03-31 |
董事简历
中英对照 | 中文 | 英文- Ali J. Satvat
-
Ali J. Satvat是KKR的私募股权投资平台的医疗保健行业团队的总监。他从2013年9月开始担任该公司的董事。他还从2014年5月开始担任Coherus BioSciences, Inc.的董事。加入KKR前，从2006年到2012年，Satvat先生担任安佰深集团（Apax Partners）的负责人，他在该公司对医疗保健行业进行投资，从2011年到2012年，担任Chiron Holdings Kinetic Concepts, Inc.与活细胞公司（LifeCell Corporation）的董事，从2008年到2012年，担任TZ Holdings （The TriZetto Group, Inc.）的董事，并积极参与了该公司的多个成功的成长型投资。在这之前，奥迪斯集团Satvat先生担任过强生发展公司（Johnson & Johnson Development Corporation）、奥迪斯集团（Audax Group）与黑石集团（Blackstone Group）的多个职位，他在该公司参与了范围广泛的交易。他在哈佛学院（Harvard College）获得文学学士学位，并在宾夕法尼亚大学沃顿商学院获得工商管理硕士学位。他还担任Healthcare Private Equity Association的董事。
Ali J. Satvat has served as a member of our board of directors since March 2016. Mr. Satvat has also served on the board of our subsidiary, Eidos Therapeutics, Inc., a clinical stage biopharmaceutical company, since June 2018. Mr. Satvat joined Kohlberg Kravis Roberts & Co. L.P., a global private equity and alternative asset management firm, in January 2012 and is a Member of KKR on the Health Care industry team within KKR’s Americas Private Equity platform. Mr. Satvat leads KKR’s Health Care Strategic Growth investing efforts and sits on the Health Care Strategic Growth Investment Committee and the Health Care Strategic Growth Portfolio Management Committee. Mr. Satvat has served as a member of the boards of directors of Coherus BioSciences, Inc. Nasdaq: CHRS, a biotechnology company, since May 2014 PRA Health Sciences, Inc. Nasdaq: PRAH, a global contract research organization, from September 2013 through April 2018 and multiple privately held companies. Prior to joining KKR, Mr. Satvat was a Principal with Apax Partners LLP, a global private equity firm, where he invested in health care from 2006 to 2012. Previously, Mr. Satvat held various positions with Johnson & Johnson Development Corporation, a venture capital subsidiary of Johnson & Johnson, Audax Group, a private equity firm, and The Blackstone Group, a global private equity and alternative asset management firm. Mr. Satvat holds an A.B. in History and Science from Harvard College and an M.B.A. in Health Care Management and Entrepreneurial Management from the Wharton School of the University of Pennsylvania. Mr. Satvat currently serves on the board of directors of the Healthcare Private Equity Association. - Ali J. Satvat是KKR的私募股权投资平台的医疗保健行业团队的总监。他从2013年9月开始担任该公司的董事。他还从2014年5月开始担任Coherus BioSciences, Inc.的董事。加入KKR前，从2006年到2012年，Satvat先生担任安佰深集团（Apax Partners）的负责人，他在该公司对医疗保健行业进行投资，从2011年到2012年，担任Chiron Holdings Kinetic Concepts, Inc.与活细胞公司（LifeCell Corporation）的董事，从2008年到2012年，担任TZ Holdings （The TriZetto Group, Inc.）的董事，并积极参与了该公司的多个成功的成长型投资。在这之前，奥迪斯集团Satvat先生担任过强生发展公司（Johnson & Johnson Development Corporation）、奥迪斯集团（Audax Group）与黑石集团（Blackstone Group）的多个职位，他在该公司参与了范围广泛的交易。他在哈佛学院（Harvard College）获得文学学士学位，并在宾夕法尼亚大学沃顿商学院获得工商管理硕士学位。他还担任Healthcare Private Equity Association的董事。
- Ali J. Satvat has served as a member of our board of directors since March 2016. Mr. Satvat has also served on the board of our subsidiary, Eidos Therapeutics, Inc., a clinical stage biopharmaceutical company, since June 2018. Mr. Satvat joined Kohlberg Kravis Roberts & Co. L.P., a global private equity and alternative asset management firm, in January 2012 and is a Member of KKR on the Health Care industry team within KKR’s Americas Private Equity platform. Mr. Satvat leads KKR’s Health Care Strategic Growth investing efforts and sits on the Health Care Strategic Growth Investment Committee and the Health Care Strategic Growth Portfolio Management Committee. Mr. Satvat has served as a member of the boards of directors of Coherus BioSciences, Inc. Nasdaq: CHRS, a biotechnology company, since May 2014 PRA Health Sciences, Inc. Nasdaq: PRAH, a global contract research organization, from September 2013 through April 2018 and multiple privately held companies. Prior to joining KKR, Mr. Satvat was a Principal with Apax Partners LLP, a global private equity firm, where he invested in health care from 2006 to 2012. Previously, Mr. Satvat held various positions with Johnson & Johnson Development Corporation, a venture capital subsidiary of Johnson & Johnson, Audax Group, a private equity firm, and The Blackstone Group, a global private equity and alternative asset management firm. Mr. Satvat holds an A.B. in History and Science from Harvard College and an M.B.A. in Health Care Management and Entrepreneurial Management from the Wharton School of the University of Pennsylvania. Mr. Satvat currently serves on the board of directors of the Healthcare Private Equity Association.
- Eric Aguiar
-
Eric Aguiar获得医学博士学位，他从2010年9月开始一直担任Invitae Corporation董事。他从2007年开始一直担任风险投资公司Thomas, McNerney & Partners的合伙人。加入该公司前，从2001年到2007年，他担任专注于医疗保健行业的风险投资公司健康保健投资（HealthCare Ventures）的常务董事。从1998年到2000年，Aguiar博士担任专注于基因送递与基因调控的生物制药公司Genovo, Inc.的首席执行官兼董事。在这之前，Aguiar博士担任一家公众所有的生物制药公司Amarin Pharmaceuticals的董事，并担任多家私人公司的董事，其中包括生命科学行业的公司。他是塔夫斯医学院Tufts School of Medicine的监事会监事，并担任美国对外关系委员会（Council on Foreign Relations）的委员。他在哈佛大学医学院（Harvard Medical School）以优异成绩获得医学博士学位；在康乃尔大学（Cornell University）获得艺术与科学文学学士学位。Aguiar博士还是鲁思研究员，并是特许财务分析师。
Eric Aguiar,has served as a member of board of directors since December 2020 and as Lead Independent Director since March 2025. Dr. Aguiar has been a partner at Aisling Capital, a healthcare-focused venture fund, since January 2016. Prior to Aisling Capital, from October 2007 to December 2015, he was a partner at Thomas, McNerney and Partners, a healthcare venture capital and growth equity fund. From 2001 to 2007, Dr. Aguiar was Managing Director of HealthCare Ventures, a healthcare-focused venture capital firm. Previously, Dr. Aguiar was Chief Executive Officer of Genovo, Inc., a privately held biopharmaceutical company, from 1998 to 2000. Dr. Aguiar has served on the board of directors of BridgeBio Pharma, Inc. (Nasdaq: BBIO) since June 2019, a public pharmaceutical company. Dr. Aguiar previously served on the boards of directors of numerous public life sciences companies, including Biohaven Pharmaceuticals, Inc. (Nasdaq: BHVN), which was acquired by Pfizer, Inc. in October 2022, and Eidos Therapeutics, Inc. (Nasdaq: EIDX) (prior to its merger with BridgeBio Pharma, Inc. (Nasdaq: BBIO) in January 2021), Invitae Corporation (Nasdaq: NVTA), and Amarin Corporation plc (NASDAQ: AMRN). Dr. Aguiar also serves on the board of directors of privately-held Garuda Therapeutics, Inc. as well as GondolaBio LLC, and previously served on the board of directors of Oriel Therapeutics, Inc. (prior to its acquisition by Novartis AG (NYSE: NVS)). Dr. Aguiar is a member of the Council on Foreign Relations. Dr. Aguiar holds a B.A. in College Scholar from Cornell University and an M.D. from Harvard Medical School, and is a Chartered Financial Analyst. - Eric Aguiar获得医学博士学位，他从2010年9月开始一直担任Invitae Corporation董事。他从2007年开始一直担任风险投资公司Thomas, McNerney & Partners的合伙人。加入该公司前，从2001年到2007年，他担任专注于医疗保健行业的风险投资公司健康保健投资（HealthCare Ventures）的常务董事。从1998年到2000年，Aguiar博士担任专注于基因送递与基因调控的生物制药公司Genovo, Inc.的首席执行官兼董事。在这之前，Aguiar博士担任一家公众所有的生物制药公司Amarin Pharmaceuticals的董事，并担任多家私人公司的董事，其中包括生命科学行业的公司。他是塔夫斯医学院Tufts School of Medicine的监事会监事，并担任美国对外关系委员会（Council on Foreign Relations）的委员。他在哈佛大学医学院（Harvard Medical School）以优异成绩获得医学博士学位；在康乃尔大学（Cornell University）获得艺术与科学文学学士学位。Aguiar博士还是鲁思研究员，并是特许财务分析师。
- Eric Aguiar,has served as a member of board of directors since December 2020 and as Lead Independent Director since March 2025. Dr. Aguiar has been a partner at Aisling Capital, a healthcare-focused venture fund, since January 2016. Prior to Aisling Capital, from October 2007 to December 2015, he was a partner at Thomas, McNerney and Partners, a healthcare venture capital and growth equity fund. From 2001 to 2007, Dr. Aguiar was Managing Director of HealthCare Ventures, a healthcare-focused venture capital firm. Previously, Dr. Aguiar was Chief Executive Officer of Genovo, Inc., a privately held biopharmaceutical company, from 1998 to 2000. Dr. Aguiar has served on the board of directors of BridgeBio Pharma, Inc. (Nasdaq: BBIO) since June 2019, a public pharmaceutical company. Dr. Aguiar previously served on the boards of directors of numerous public life sciences companies, including Biohaven Pharmaceuticals, Inc. (Nasdaq: BHVN), which was acquired by Pfizer, Inc. in October 2022, and Eidos Therapeutics, Inc. (Nasdaq: EIDX) (prior to its merger with BridgeBio Pharma, Inc. (Nasdaq: BBIO) in January 2021), Invitae Corporation (Nasdaq: NVTA), and Amarin Corporation plc (NASDAQ: AMRN). Dr. Aguiar also serves on the board of directors of privately-held Garuda Therapeutics, Inc. as well as GondolaBio LLC, and previously served on the board of directors of Oriel Therapeutics, Inc. (prior to its acquisition by Novartis AG (NYSE: NVS)). Dr. Aguiar is a member of the Council on Foreign Relations. Dr. Aguiar holds a B.A. in College Scholar from Cornell University and an M.D. from Harvard Medical School, and is a Chartered Financial Analyst.
- Charles Homcy
-
Charles Homcy，他也是BridgeBio Pharma， Inc.的联合创始人，自2018年11月起担任该公司董事，自2019年2月起担任制药董事长，自2020年2月起担任首席董事。Homcy博士于2010年加入风险投资公司Third Rock Ventures，在那里他是合伙人，直到2019年10月，现在担任顾问职务。2003年，他共同创立了Portola Pharmaceuticals（临床生物技术公司），并担任总裁兼首席执行官（直到2010年）。在此之前，Homcy博士曾担任Millennium Pharmaceuticals， Inc.（生物制药公司，2002年收购COR Therapeutics， Inc.）的研发总裁。他于1995年加入COR Therapeutics， Inc.（一家生物制药公司），担任研发执行副总裁，并于1998年至2002年担任公司董事。他曾担任American cyanamide - lederle Laboratories医学研究部门的总裁。1997年至2008年，他是加州大学旧金山医学院的临床医学教授，以及旧金山退伍军人事务医院的主治医生。他之前是Massachusetts General Hospital心脏部门的成员，也是Harvard Medical School的医学副教授。他持有约翰霍普金斯大学的学士学位和医学博士学位，目前担任其董事会成员。Homcy博士是多家生物技术公司的联合创始人，包括Global Blood Therapeutics、MyoKardia、Relay Therapeutics、Goldfinch、Pliant、Ambys Medicines和Maze Therapeutics。
Charles Homcy,is Maze Therapeutics, Inc. co-founder and has served as the chairman of Maze Therapeutics, Inc. board of directors since June 2018. Dr. Homcy previously served as a partner at Third Rock Ventures, a venture capital firm, from September 2010 to October 2019 where he currently serves in an advisory capacity. Dr. Homcy is also a co-founder of BridgeBio Pharma, Inc., a publicly traded biotechnology company, and has served as a member of its board of directors since November 2018, as Chairman of Pharmaceuticals since February 2019, and as lead director since February 2020. In 2003, Dr. Homcy co-founded Portola Pharmaceuticals, LLC, a clinical biotechnology company, and served as President and Chief Executive Officer until 2010. Prior to that, Dr. Homcy served as director and the President of Research and Development at Millennium Pharmaceuticals, Inc. He was previously President of the medical research division of American Cyanamid & Chemical Corporation's American Cyanamid-Lederle Laboratories. Dr. Homcy was a clinical professor of medicine at the University of California, San Francisco Medical School, and attending physician at the San Francisco Veterans Affairs Hospital from 1997 to 2008. He was previously a member of the Cardiac Unit of the Massachusetts General Hospital and an Associate Professor of Medicine at Harvard Medical School. Dr. Homcy holds an A.B. in Biology and an M.D. from Johns Hopkins University and is an Emeritus Trustee. Dr. Homcy is a co-founder of multiple privately held biotechnology companies including Global Blood Therapeutics, Inc., MyoKardia, Inc., Relay Therapeutics, Inc., Pliant Therapeutics Inc., and Marea Therapeutics. - Charles Homcy，他也是BridgeBio Pharma， Inc.的联合创始人，自2018年11月起担任该公司董事，自2019年2月起担任制药董事长，自2020年2月起担任首席董事。Homcy博士于2010年加入风险投资公司Third Rock Ventures，在那里他是合伙人，直到2019年10月，现在担任顾问职务。2003年，他共同创立了Portola Pharmaceuticals（临床生物技术公司），并担任总裁兼首席执行官（直到2010年）。在此之前，Homcy博士曾担任Millennium Pharmaceuticals， Inc.（生物制药公司，2002年收购COR Therapeutics， Inc.）的研发总裁。他于1995年加入COR Therapeutics， Inc.（一家生物制药公司），担任研发执行副总裁，并于1998年至2002年担任公司董事。他曾担任American cyanamide - lederle Laboratories医学研究部门的总裁。1997年至2008年，他是加州大学旧金山医学院的临床医学教授，以及旧金山退伍军人事务医院的主治医生。他之前是Massachusetts General Hospital心脏部门的成员，也是Harvard Medical School的医学副教授。他持有约翰霍普金斯大学的学士学位和医学博士学位，目前担任其董事会成员。Homcy博士是多家生物技术公司的联合创始人，包括Global Blood Therapeutics、MyoKardia、Relay Therapeutics、Goldfinch、Pliant、Ambys Medicines和Maze Therapeutics。
- Charles Homcy,is Maze Therapeutics, Inc. co-founder and has served as the chairman of Maze Therapeutics, Inc. board of directors since June 2018. Dr. Homcy previously served as a partner at Third Rock Ventures, a venture capital firm, from September 2010 to October 2019 where he currently serves in an advisory capacity. Dr. Homcy is also a co-founder of BridgeBio Pharma, Inc., a publicly traded biotechnology company, and has served as a member of its board of directors since November 2018, as Chairman of Pharmaceuticals since February 2019, and as lead director since February 2020. In 2003, Dr. Homcy co-founded Portola Pharmaceuticals, LLC, a clinical biotechnology company, and served as President and Chief Executive Officer until 2010. Prior to that, Dr. Homcy served as director and the President of Research and Development at Millennium Pharmaceuticals, Inc. He was previously President of the medical research division of American Cyanamid & Chemical Corporation's American Cyanamid-Lederle Laboratories. Dr. Homcy was a clinical professor of medicine at the University of California, San Francisco Medical School, and attending physician at the San Francisco Veterans Affairs Hospital from 1997 to 2008. He was previously a member of the Cardiac Unit of the Massachusetts General Hospital and an Associate Professor of Medicine at Harvard Medical School. Dr. Homcy holds an A.B. in Biology and an M.D. from Johns Hopkins University and is an Emeritus Trustee. Dr. Homcy is a co-founder of multiple privately held biotechnology companies including Global Blood Therapeutics, Inc., MyoKardia, Inc., Relay Therapeutics, Inc., Pliant Therapeutics Inc., and Marea Therapeutics.
- Neil Kumar
-
Neil Kumar是我们的联合创始人，自2015年4月起担任我们的首席执行官兼董事会成员。库马尔博士还曾担任我们子公司EidosTherapeutics，Inc.的首席执行官。纳斯达克股票代码:EIDX，一家临床阶段生物制药公司，自2016年3月起担任EIDOS Therapeutics’；董事会成员。在此之前，他担任Myokardia，Inc.业务发展临时Vice President。纳斯达克股票代码:MYOK，一家临床阶段生物制药公司，从2012年到2014年。在此之前，Kumar博士从2011年到2014年担任Third Rock Ventures（一家风险投资公司）的负责人。加入Third Rock Ventures公司之前，他曾担任McKinsey&Company（全球管理咨询公司）的副校长（从2007年到2011年）。他在斯坦福大学（Stanford University）获得化学工程学士学位和硕士学位，并在麻省理工学院（Massachusetts Institute of Technology）获得化学工程博士学位。
Neil Kumar,served as BBOT's Chief Executive Officer and President from August 2016 to April 2024. He is a co-founder and has been the Chief Executive Officer and a member of the board of directors of BridgeBio Pharma (Nasdaq: BBIO) since April 2015. Dr. Kumar has also served as the Chief Executive Officer of BridgeBio Pharma's subsidiary, Eidos Therapeutics, Inc. (formerly Nasdaq: EIDX), and a member of its board of directors since March 2016. Prior to co-founding BridgeBio Pharma, he was the interim Vice President of Business Development at MyoKardia, Inc. (formerly Nasdaq: MYOK, acquired by Bristol Myers Squibb), from 2012 to 2014. He was a principal at Third Rock Ventures from 2011 to 2014 and an associate principal at McKinsey & Company from 2007 to 2011. Dr. Kumar has served on the board of directors of LianBio (formerly Nasdaq: LIAN) since October 2019. He received his B.S. and M.S. degrees in Chemical Engineering from Stanford University and his Ph.D. in Chemical Engineering from the Massachusetts Institute of Technology. - Neil Kumar是我们的联合创始人，自2015年4月起担任我们的首席执行官兼董事会成员。库马尔博士还曾担任我们子公司EidosTherapeutics，Inc.的首席执行官。纳斯达克股票代码:EIDX，一家临床阶段生物制药公司，自2016年3月起担任EIDOS Therapeutics’；董事会成员。在此之前，他担任Myokardia，Inc.业务发展临时Vice President。纳斯达克股票代码:MYOK，一家临床阶段生物制药公司，从2012年到2014年。在此之前，Kumar博士从2011年到2014年担任Third Rock Ventures（一家风险投资公司）的负责人。加入Third Rock Ventures公司之前，他曾担任McKinsey&Company（全球管理咨询公司）的副校长（从2007年到2011年）。他在斯坦福大学（Stanford University）获得化学工程学士学位和硕士学位，并在麻省理工学院（Massachusetts Institute of Technology）获得化学工程博士学位。
- Neil Kumar,served as BBOT's Chief Executive Officer and President from August 2016 to April 2024. He is a co-founder and has been the Chief Executive Officer and a member of the board of directors of BridgeBio Pharma (Nasdaq: BBIO) since April 2015. Dr. Kumar has also served as the Chief Executive Officer of BridgeBio Pharma's subsidiary, Eidos Therapeutics, Inc. (formerly Nasdaq: EIDX), and a member of its board of directors since March 2016. Prior to co-founding BridgeBio Pharma, he was the interim Vice President of Business Development at MyoKardia, Inc. (formerly Nasdaq: MYOK, acquired by Bristol Myers Squibb), from 2012 to 2014. He was a principal at Third Rock Ventures from 2011 to 2014 and an associate principal at McKinsey & Company from 2007 to 2011. Dr. Kumar has served on the board of directors of LianBio (formerly Nasdaq: LIAN) since October 2019. He received his B.S. and M.S. degrees in Chemical Engineering from Stanford University and his Ph.D. in Chemical Engineering from the Massachusetts Institute of Technology.
- Richard H. Scheller
-
RichardH.Scheller自2018年1月起担任董事会成员，自2019年1月起担任研发主席。Scheller博士自2015年以来一直担任23Andme（一家个人遗传学公司）的首席科学官兼治疗学主管。此前，Scheller博士曾于2001年2月至2014年12月担任生物技术公司Genentech，Inc.研究与早期开发执行Vice President和执行委员会成员。Scheller从2009年1月到2014年12月担任Hoffmann-La Roche Ltd（一家制药公司）扩大执行委员会成员。Scheller博士目前担任Xenon PharmaceuticalsInc.（一家临床阶段生物制药公司）、ORICPharmaceuticals，Inc.（一家生物制药公司）、Affinita Biotech，Inc.（一家临床前阶段生物制药公司）和Alector，Inc.（一家临床阶段生物制药公司）的董事。Scheller博士拥有工商管理硕士学位。the University of Wisconsin-Madison的生物化学博士学位和California Institute of Technology的化学博士学位。他在哥伦比亚大学（Columbia University）完成分子神经生物学博士后学位，也是加州理工学院（California Institute of Technology）的博士后研究员。
Richard H. Scheller has served as a member of our board of directors since January 2018 and as our Chairman of Research & Development effective as of January 2019. Dr. Scheller has been Chief Science Officer and Head of Therapeutics at 23andMe, a personal genetics company, since 2015. Previously, Dr. Scheller was the Executive Vice President of Research and Early Development and a member of the Executive Committee at Genentech, Inc., a biotechnology corporation, from February 2001 to December 2014. From January 2009 to December 2014 Dr. Scheller was also a member of the Enlarged Executive Committee at Hoffmann-La Roche Ltd, a pharmaceutical company. Dr. Scheller currently serves as a member of the board of directors of Xenon Pharmaceuticals Inc., a clinical stage biopharmaceutical company, ORIC Pharmaceuticals, Inc., a biopharmaceutical company, Affinita Biotech, Inc., a preclinical stage biotech company and Alector, Inc., a clinical-stage biopharmaceutical company. Dr. Scheller holds a B.Sc. in Biochemistry from the University of Wisconsin-Madison and a Ph.D. in Chemistry from the California Institute of Technology. He completed his post-doctorate in Molecular Neurobiology at Columbia University and was also a post-doctorate fellow at California Institute of Technology. - RichardH.Scheller自2018年1月起担任董事会成员，自2019年1月起担任研发主席。Scheller博士自2015年以来一直担任23Andme（一家个人遗传学公司）的首席科学官兼治疗学主管。此前，Scheller博士曾于2001年2月至2014年12月担任生物技术公司Genentech，Inc.研究与早期开发执行Vice President和执行委员会成员。Scheller从2009年1月到2014年12月担任Hoffmann-La Roche Ltd（一家制药公司）扩大执行委员会成员。Scheller博士目前担任Xenon PharmaceuticalsInc.（一家临床阶段生物制药公司）、ORICPharmaceuticals，Inc.（一家生物制药公司）、Affinita Biotech，Inc.（一家临床前阶段生物制药公司）和Alector，Inc.（一家临床阶段生物制药公司）的董事。Scheller博士拥有工商管理硕士学位。the University of Wisconsin-Madison的生物化学博士学位和California Institute of Technology的化学博士学位。他在哥伦比亚大学（Columbia University）完成分子神经生物学博士后学位，也是加州理工学院（California Institute of Technology）的博士后研究员。
- Richard H. Scheller has served as a member of our board of directors since January 2018 and as our Chairman of Research & Development effective as of January 2019. Dr. Scheller has been Chief Science Officer and Head of Therapeutics at 23andMe, a personal genetics company, since 2015. Previously, Dr. Scheller was the Executive Vice President of Research and Early Development and a member of the Executive Committee at Genentech, Inc., a biotechnology corporation, from February 2001 to December 2014. From January 2009 to December 2014 Dr. Scheller was also a member of the Enlarged Executive Committee at Hoffmann-La Roche Ltd, a pharmaceutical company. Dr. Scheller currently serves as a member of the board of directors of Xenon Pharmaceuticals Inc., a clinical stage biopharmaceutical company, ORIC Pharmaceuticals, Inc., a biopharmaceutical company, Affinita Biotech, Inc., a preclinical stage biotech company and Alector, Inc., a clinical-stage biopharmaceutical company. Dr. Scheller holds a B.Sc. in Biochemistry from the University of Wisconsin-Madison and a Ph.D. in Chemistry from the California Institute of Technology. He completed his post-doctorate in Molecular Neurobiology at Columbia University and was also a post-doctorate fellow at California Institute of Technology.
- James C. Momtazee
-
James C. Momtazee，自2021年9月起担任Roivant董事。Momtazee先生是专门的医疗保健投资公司Patient Square Capital的管理合伙人。Momtazee先生拥有超过28年的投资和收购经验，其中绝大多数专注于医疗保健行业。在创立Patient Square之前，他自1996年起在KKR公司（“KKR”）担任多个职位。2001年，他帮助组建了KKR的医疗行业集团，并管理该团队超过10年。Momtazee先生目前还担任Enavate Sciences、BridgeBio Pharma、Apollo Therapeutics、Kriya Therapeutics、Alladapt Immunotherapeutics、Elevage Medical Technologies和医疗器械制造商协会的董事会成员，并曾担任其他多家医疗保健公司的董事会成员，包括PRA健康科学公司（首席独立董事）、Envision Healthcare、Heartland Dental、Ajax Health、Global Medical Response、BrightSpring Health Services、Covenant Surgical Partners、Entellus医疗公司、EchoNous、Spirox，Inc.、Arbor Pharmaceuticals、Lake Region Medical、HCA健康护理、爵士制药和Alliance Imaging。Momtazee先生于2020年10月至2021年10月担任Montes Archimedes Acquisition Corp的董事长、首席执行官兼总裁。他在斯坦福大学获得了A.B.学位，在斯坦福大学商学院获得了MBA学位。
James C. Momtazee,is the Managing Partner of Patient Square Capital, LP, a dedicated health care investing firm. Mr. Momtazee has over 29 years of investment and acquisition experience, the vast majority of which was focused on the health care sector. Prior to founding Patient Square, he held various positions at KKR & Co., Inc. since 1996. He helped form KKR's health care industry group in 2001 and ran that team for over 10 years. Mr. Momtazee also serves on the boards of directors of Apollo Therapeutics, Kriya Therapeutics, Enavate Sciences, Elevage Medical Technologies, Syneos Health, GondolaBio, Hanger, BridgeBio Pharma and the Medical Device Manufacturers Association. Mr. Momtazee was Chairman, CEO and President of Montes Archimedes Acquisition Corp. from October 2020 until October 2021. He received an A.B. from Stanford University and an M.B.A. from the Stanford Graduate School of Business. - James C. Momtazee，自2021年9月起担任Roivant董事。Momtazee先生是专门的医疗保健投资公司Patient Square Capital的管理合伙人。Momtazee先生拥有超过28年的投资和收购经验，其中绝大多数专注于医疗保健行业。在创立Patient Square之前，他自1996年起在KKR公司（“KKR”）担任多个职位。2001年，他帮助组建了KKR的医疗行业集团，并管理该团队超过10年。Momtazee先生目前还担任Enavate Sciences、BridgeBio Pharma、Apollo Therapeutics、Kriya Therapeutics、Alladapt Immunotherapeutics、Elevage Medical Technologies和医疗器械制造商协会的董事会成员，并曾担任其他多家医疗保健公司的董事会成员，包括PRA健康科学公司（首席独立董事）、Envision Healthcare、Heartland Dental、Ajax Health、Global Medical Response、BrightSpring Health Services、Covenant Surgical Partners、Entellus医疗公司、EchoNous、Spirox，Inc.、Arbor Pharmaceuticals、Lake Region Medical、HCA健康护理、爵士制药和Alliance Imaging。Momtazee先生于2020年10月至2021年10月担任Montes Archimedes Acquisition Corp的董事长、首席执行官兼总裁。他在斯坦福大学获得了A.B.学位，在斯坦福大学商学院获得了MBA学位。
- James C. Momtazee,is the Managing Partner of Patient Square Capital, LP, a dedicated health care investing firm. Mr. Momtazee has over 29 years of investment and acquisition experience, the vast majority of which was focused on the health care sector. Prior to founding Patient Square, he held various positions at KKR & Co., Inc. since 1996. He helped form KKR's health care industry group in 2001 and ran that team for over 10 years. Mr. Momtazee also serves on the boards of directors of Apollo Therapeutics, Kriya Therapeutics, Enavate Sciences, Elevage Medical Technologies, Syneos Health, GondolaBio, Hanger, BridgeBio Pharma and the Medical Device Manufacturers Association. Mr. Momtazee was Chairman, CEO and President of Montes Archimedes Acquisition Corp. from October 2020 until October 2021. He received an A.B. from Stanford University and an M.B.A. from the Stanford Graduate School of Business.
- Frank McCormick
-
Frank McCormick，博士，2003年7月以来一直是董事。自1998年以来他一直是加州大学旧金山分校Helen Diller Family 综合癌症中心董事，他目前是加州大学旧金山分校医学院副院长。他是加州大学旧金山分校微生物学和免疫学部门肿瘤和癌症研究所的David A. Wood教授和肿瘤学E. Dixon Heise特聘教授。他从2012年4月到2013年4月担任美国癌症研究协会总裁，这是一个科学组织，使命是通过研究、教育、沟通和协作预防和治疗癌症。他从1992年到1998年是Onyx Pharmaceuticals公司的创始人和首席科学官，一家生物技术公司。从1991年到1992年他担任Chiron公司治疗研究公司副总裁，一家制药公司并从1981年到1990年他担任Cetus公司发现研究副总裁，一家生物技术公司。他是一些最著名的国际癌症的出版物编辑部成员，作为多个癌症研究组织的董事会成员或顾问。他和Dr. Allen Smith是英国伦敦皇家癌症研究基金的一位博士后研究员，和Seymour S. Cohen教授是纽约州立大学斯托尼布鲁克分校研究员。他持有伯明翰大学的生物化学学士学位，英国剑桥大学的生物化学博士学位。
Frank McCormick has served as a member of our board of directors since December 2014. Dr. McCormick has served as the Chairman of Oncology at BridgeBio Pharma, Inc. since April 2019. He has held the position of Director the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, a multidisciplinary research and medical care organization and served as Associate Dean of the University of California, San Francisco School of Medicine from 1997 to 2014. Prior to joining the University of California, San Francisco faculty, Dr. McCormick pursued cancer-related work with several biotechnology firms, including Cetus Corporation as Director of Molecular Biology from 1981 to 1990 and Vice President of Research from 1990 to 1991 and Chiron Corporation as Vice President of Research from 1991 to 1992. In 1992 he founded Onyx Pharmaceuticals Inc. and served as its Chief Scientific Officer until 1996. He also served as a member of the board of directors of Aduro Biotech, Inc., a publicly traded biotechnology company, from 2010 to February 2019. Dr. McCormick received his B.Sc. in biochemistry from the University of Birmingham, and his Ph.D. in biochemistry from the University of Cambridge and held postdoctoral fellowships in the U.S. at the State University of New York at Stony Brook and in London at the Imperial Cancer Research Fund. Dr. McCormick is a Fellow of the Royal Society, an institution dedicated to science, since 1996 a member of the National Academy of Sciences since 2014 and has served as President, from 2012 to 2013 for the American Association for Cancer Research. Since 2013 Dr. McCormick has led the National Cancer Institute’s Ras Initiative at the Frederick National Laboratories for Cancer Research overseeing the national effort to develop therapies against Ras-driven cancers. - Frank McCormick，博士，2003年7月以来一直是董事。自1998年以来他一直是加州大学旧金山分校Helen Diller Family 综合癌症中心董事，他目前是加州大学旧金山分校医学院副院长。他是加州大学旧金山分校微生物学和免疫学部门肿瘤和癌症研究所的David A. Wood教授和肿瘤学E. Dixon Heise特聘教授。他从2012年4月到2013年4月担任美国癌症研究协会总裁，这是一个科学组织，使命是通过研究、教育、沟通和协作预防和治疗癌症。他从1992年到1998年是Onyx Pharmaceuticals公司的创始人和首席科学官，一家生物技术公司。从1991年到1992年他担任Chiron公司治疗研究公司副总裁，一家制药公司并从1981年到1990年他担任Cetus公司发现研究副总裁，一家生物技术公司。他是一些最著名的国际癌症的出版物编辑部成员，作为多个癌症研究组织的董事会成员或顾问。他和Dr. Allen Smith是英国伦敦皇家癌症研究基金的一位博士后研究员，和Seymour S. Cohen教授是纽约州立大学斯托尼布鲁克分校研究员。他持有伯明翰大学的生物化学学士学位，英国剑桥大学的生物化学博士学位。
- Frank McCormick has served as a member of our board of directors since December 2014. Dr. McCormick has served as the Chairman of Oncology at BridgeBio Pharma, Inc. since April 2019. He has held the position of Director the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, a multidisciplinary research and medical care organization and served as Associate Dean of the University of California, San Francisco School of Medicine from 1997 to 2014. Prior to joining the University of California, San Francisco faculty, Dr. McCormick pursued cancer-related work with several biotechnology firms, including Cetus Corporation as Director of Molecular Biology from 1981 to 1990 and Vice President of Research from 1990 to 1991 and Chiron Corporation as Vice President of Research from 1991 to 1992. In 1992 he founded Onyx Pharmaceuticals Inc. and served as its Chief Scientific Officer until 1996. He also served as a member of the board of directors of Aduro Biotech, Inc., a publicly traded biotechnology company, from 2010 to February 2019. Dr. McCormick received his B.Sc. in biochemistry from the University of Birmingham, and his Ph.D. in biochemistry from the University of Cambridge and held postdoctoral fellowships in the U.S. at the State University of New York at Stony Brook and in London at the Imperial Cancer Research Fund. Dr. McCormick is a Fellow of the Royal Society, an institution dedicated to science, since 1996 a member of the National Academy of Sciences since 2014 and has served as President, from 2012 to 2013 for the American Association for Cancer Research. Since 2013 Dr. McCormick has led the National Cancer Institute’s Ras Initiative at the Frederick National Laboratories for Cancer Research overseeing the national effort to develop therapies against Ras-driven cancers.
高管简历
中英对照 | 中文 | 英文- Neil Kumar
Neil Kumar是我们的联合创始人，自2015年4月起担任我们的首席执行官兼董事会成员。库马尔博士还曾担任我们子公司EidosTherapeutics，Inc.的首席执行官。纳斯达克股票代码:EIDX，一家临床阶段生物制药公司，自2016年3月起担任EIDOS Therapeutics’；董事会成员。在此之前，他担任Myokardia，Inc.业务发展临时Vice President。纳斯达克股票代码:MYOK，一家临床阶段生物制药公司，从2012年到2014年。在此之前，Kumar博士从2011年到2014年担任Third Rock Ventures（一家风险投资公司）的负责人。加入Third Rock Ventures公司之前，他曾担任McKinsey&Company（全球管理咨询公司）的副校长（从2007年到2011年）。他在斯坦福大学（Stanford University）获得化学工程学士学位和硕士学位，并在麻省理工学院（Massachusetts Institute of Technology）获得化学工程博士学位。
Neil Kumar,served as BBOT's Chief Executive Officer and President from August 2016 to April 2024. He is a co-founder and has been the Chief Executive Officer and a member of the board of directors of BridgeBio Pharma (Nasdaq: BBIO) since April 2015. Dr. Kumar has also served as the Chief Executive Officer of BridgeBio Pharma's subsidiary, Eidos Therapeutics, Inc. (formerly Nasdaq: EIDX), and a member of its board of directors since March 2016. Prior to co-founding BridgeBio Pharma, he was the interim Vice President of Business Development at MyoKardia, Inc. (formerly Nasdaq: MYOK, acquired by Bristol Myers Squibb), from 2012 to 2014. He was a principal at Third Rock Ventures from 2011 to 2014 and an associate principal at McKinsey & Company from 2007 to 2011. Dr. Kumar has served on the board of directors of LianBio (formerly Nasdaq: LIAN) since October 2019. He received his B.S. and M.S. degrees in Chemical Engineering from Stanford University and his Ph.D. in Chemical Engineering from the Massachusetts Institute of Technology.- Neil Kumar是我们的联合创始人，自2015年4月起担任我们的首席执行官兼董事会成员。库马尔博士还曾担任我们子公司EidosTherapeutics，Inc.的首席执行官。纳斯达克股票代码:EIDX，一家临床阶段生物制药公司，自2016年3月起担任EIDOS Therapeutics’；董事会成员。在此之前，他担任Myokardia，Inc.业务发展临时Vice President。纳斯达克股票代码:MYOK，一家临床阶段生物制药公司，从2012年到2014年。在此之前，Kumar博士从2011年到2014年担任Third Rock Ventures（一家风险投资公司）的负责人。加入Third Rock Ventures公司之前，他曾担任McKinsey&Company（全球管理咨询公司）的副校长（从2007年到2011年）。他在斯坦福大学（Stanford University）获得化学工程学士学位和硕士学位，并在麻省理工学院（Massachusetts Institute of Technology）获得化学工程博士学位。
- Neil Kumar,served as BBOT's Chief Executive Officer and President from August 2016 to April 2024. He is a co-founder and has been the Chief Executive Officer and a member of the board of directors of BridgeBio Pharma (Nasdaq: BBIO) since April 2015. Dr. Kumar has also served as the Chief Executive Officer of BridgeBio Pharma's subsidiary, Eidos Therapeutics, Inc. (formerly Nasdaq: EIDX), and a member of its board of directors since March 2016. Prior to co-founding BridgeBio Pharma, he was the interim Vice President of Business Development at MyoKardia, Inc. (formerly Nasdaq: MYOK, acquired by Bristol Myers Squibb), from 2012 to 2014. He was a principal at Third Rock Ventures from 2011 to 2014 and an associate principal at McKinsey & Company from 2007 to 2011. Dr. Kumar has served on the board of directors of LianBio (formerly Nasdaq: LIAN) since October 2019. He received his B.S. and M.S. degrees in Chemical Engineering from Stanford University and his Ph.D. in Chemical Engineering from the Massachusetts Institute of Technology.
- Uma Sinha
Uma Sinha自2016年4月起担任首席科学官，并担任Bridgebio其他子公司的首席科学官，包括Eidos Therapeutics。在此之前，辛哈博士担任全球血液疗法公司的首席科学官。纳斯达克股票代码:GBT，一家临床阶段的生物制药公司，2014年至2015年，此前曾于2013年至2014年担任研究高级副总裁。她是PortolaPharmaceuticals，Inc.生物系主任Vice President。从2010年到2012年，PTLA是一家临床阶段的生物技术公司，从2004年到2010年，它是转化生物学的Vice President。此前，Sinha博士在生物制药公司Millennium Pharmaceuticals，Inc.和生物制药公司COR Therapeutics，Inc.担任高级研究职位。Sinha博士在乔治亚大学（University of Georgia）获得生物化学博士学位，并获得理学学士学位。Presidency College化学荣誉。
Uma Sinha has served as Chief Scientific Officer since April 2016 and serves as the chief scientific officer of other BridgeBio subsidiaries, including Eidos Therapeutics. Prior to that, Dr. Sinha served as chief scientific officer of Global Blood Therapeutics, Inc. Nasdaq: GBT, a clinical stage biopharmaceutical company, from 2014 to 2015 and previously as senior vice president of research from 2013 to 2014. She was vice president, head of biology at Portola Pharmaceuticals, Inc. Nasdaq: PTLA, a clinical stage biotechnology company, from 2010 to 2012 and was the vice president of translational biology from 2004 to 2010. Previously, Dr. Sinha held senior research positions at Millennium Pharmaceuticals, Inc., a biopharmaceutical company, and COR Therapeutics, Inc., a biopharmaceutical company. Dr. Sinha received her Ph.D. in biochemistry from the University of Georgia and her B.Sc. with honors in chemistry from Presidency College.- Uma Sinha自2016年4月起担任首席科学官，并担任Bridgebio其他子公司的首席科学官，包括Eidos Therapeutics。在此之前，辛哈博士担任全球血液疗法公司的首席科学官。纳斯达克股票代码:GBT，一家临床阶段的生物制药公司，2014年至2015年，此前曾于2013年至2014年担任研究高级副总裁。她是PortolaPharmaceuticals，Inc.生物系主任Vice President。从2010年到2012年，PTLA是一家临床阶段的生物技术公司，从2004年到2010年，它是转化生物学的Vice President。此前，Sinha博士在生物制药公司Millennium Pharmaceuticals，Inc.和生物制药公司COR Therapeutics，Inc.担任高级研究职位。Sinha博士在乔治亚大学（University of Georgia）获得生物化学博士学位，并获得理学学士学位。Presidency College化学荣誉。
- Uma Sinha has served as Chief Scientific Officer since April 2016 and serves as the chief scientific officer of other BridgeBio subsidiaries, including Eidos Therapeutics. Prior to that, Dr. Sinha served as chief scientific officer of Global Blood Therapeutics, Inc. Nasdaq: GBT, a clinical stage biopharmaceutical company, from 2014 to 2015 and previously as senior vice president of research from 2013 to 2014. She was vice president, head of biology at Portola Pharmaceuticals, Inc. Nasdaq: PTLA, a clinical stage biotechnology company, from 2010 to 2012 and was the vice president of translational biology from 2004 to 2010. Previously, Dr. Sinha held senior research positions at Millennium Pharmaceuticals, Inc., a biopharmaceutical company, and COR Therapeutics, Inc., a biopharmaceutical company. Dr. Sinha received her Ph.D. in biochemistry from the University of Georgia and her B.Sc. with honors in chemistry from Presidency College.
- Brian C. Stephenson
BrianC.Stephenson自2018年10月起担任我们的首席财务官。在加入我们之前，Stephenson博士于2015年至2018年担任特殊情况投资基金Capital IP Investment Partners的合伙人兼生命科学主管。2011年至2014年，Stephenson博士担任投资银行Vice President Leerink Partners的董事。在此之前，Stephenson博士是麦肯锡公司（McKinsey&Company）的业务经理，该公司是一家全球管理咨询公司。他在麻省理工学院（Massachusetts Institute of Technology）获得化学工程博士学位和硕士学位，在杨百翰大学（Brigham Young University）获得化学工程学士学位。Stephenson博士也是特许金融分析师特许持有人。
Brian C. Stephenson has served as our Chief Financial Officer since October 2018. Prior to joining us, Dr. Stephenson served as Partner and the Head of Life Sciences for Capital IP Investment Partners, a special situation investment fund, from 2015 to 2018. From 2011 to 2014 Dr. Stephenson was a Director/Vice President Leerink Partners, an investment bank. Prior to that, Dr. Stephenson was an Engagement Manager at McKinsey & Company, a worldwide management consulting firm. He received his Ph.D. and M.S. degrees in chemical engineering from the Massachusetts Institute of Technology and his B.S. in chemical engineering from Brigham Young University. Dr. Stephenson is also a Chartered Financial Analyst charterholder.- BrianC.Stephenson自2018年10月起担任我们的首席财务官。在加入我们之前，Stephenson博士于2015年至2018年担任特殊情况投资基金Capital IP Investment Partners的合伙人兼生命科学主管。2011年至2014年，Stephenson博士担任投资银行Vice President Leerink Partners的董事。在此之前，Stephenson博士是麦肯锡公司（McKinsey&Company）的业务经理，该公司是一家全球管理咨询公司。他在麻省理工学院（Massachusetts Institute of Technology）获得化学工程博士学位和硕士学位，在杨百翰大学（Brigham Young University）获得化学工程学士学位。Stephenson博士也是特许金融分析师特许持有人。
- Brian C. Stephenson has served as our Chief Financial Officer since October 2018. Prior to joining us, Dr. Stephenson served as Partner and the Head of Life Sciences for Capital IP Investment Partners, a special situation investment fund, from 2015 to 2018. From 2011 to 2014 Dr. Stephenson was a Director/Vice President Leerink Partners, an investment bank. Prior to that, Dr. Stephenson was an Engagement Manager at McKinsey & Company, a worldwide management consulting firm. He received his Ph.D. and M.S. degrees in chemical engineering from the Massachusetts Institute of Technology and his B.S. in chemical engineering from Brigham Young University. Dr. Stephenson is also a Chartered Financial Analyst charterholder.
- Cameron Turtle
Cameron Turtle自2018年1月以来一直担任我们的高级副总裁，投资组合管理和企业发展，并于2017年2月至2017年12月担任投资组合管理董事。Turtle先生自2017年2月起还曾在我们的子公司Eidos Therapeutics工作，目前担任首席商务官。Turtle先生曾于2017年2月至2018年3月担任我们的子公司Navire Pharmaceuticals，Inc.的业务开发和运营Vice President。从2016年8月至2017年1月，乌龟先生是麦肯锡公司的顾问。Turtle先生在华盛顿大学（University of Washington）以优异成绩获得生物工程学士学位，并获得哲学博士学位。他在牛津大学圣约翰学院（University of Oxford，St.John&8217；s College）获得心血管医学博士学位，在那里他曾是一名罗德学者。
Cameron Turtle has served as our Senior Vice President, Portfolio Management and Corporate Development, since January 2018 and served as a Director, Portfolio Management, from February 2017 to December 2017. Mr. Turtle has also worked for our subsidiary, Eidos Therapeutics, since February 2017 currently as the chief business officer. Mr. Turtle previously worked as vice president of business development and operations for our subsidiary, Navire Pharmaceuticals, Inc., from February 2017 to March 2018. From August 2016 to January 2017 Mr. Turtle was a consultant at McKinsey & Company. Mr. Turtle received his B.S. with honors in bioengineering from the University of Washington and his D. Phil. in cardiovascular medicine from University of Oxford, St. John’s College, where he was a Rhodes Scholar.- Cameron Turtle自2018年1月以来一直担任我们的高级副总裁，投资组合管理和企业发展，并于2017年2月至2017年12月担任投资组合管理董事。Turtle先生自2017年2月起还曾在我们的子公司Eidos Therapeutics工作，目前担任首席商务官。Turtle先生曾于2017年2月至2018年3月担任我们的子公司Navire Pharmaceuticals，Inc.的业务开发和运营Vice President。从2016年8月至2017年1月，乌龟先生是麦肯锡公司的顾问。Turtle先生在华盛顿大学（University of Washington）以优异成绩获得生物工程学士学位，并获得哲学博士学位。他在牛津大学圣约翰学院（University of Oxford，St.John&8217；s College）获得心血管医学博士学位，在那里他曾是一名罗德学者。
- Cameron Turtle has served as our Senior Vice President, Portfolio Management and Corporate Development, since January 2018 and served as a Director, Portfolio Management, from February 2017 to December 2017. Mr. Turtle has also worked for our subsidiary, Eidos Therapeutics, since February 2017 currently as the chief business officer. Mr. Turtle previously worked as vice president of business development and operations for our subsidiary, Navire Pharmaceuticals, Inc., from February 2017 to March 2018. From August 2016 to January 2017 Mr. Turtle was a consultant at McKinsey & Company. Mr. Turtle received his B.S. with honors in bioengineering from the University of Washington and his D. Phil. in cardiovascular medicine from University of Oxford, St. John’s College, where he was a Rhodes Scholar.
- Michael Henderson
Michael Henderson，自2023年6月起担任Apogee Therapeutics，Inc.董事会成员，自2022年起担任Apogee Therapeutics，LLC管理委员会成员，自2022年9月起担任Apogee Therapeutics，Inc.首席执行官。亨德森博士是一位经验丰富的生物技术高管，在商业领导、药物开发和商业战略方面具有专长。迄今为止，他领导了多家公司的创建，启动了大量的药物开发项目，并带领团队获得了两项FDA的批准。在加入Apogee之前，Henderson博士于2020年1月至2022年9月担任处于商业化阶段的生物制药公司BridgeBio Pharma（纳斯达克：BBIO）的首席商务官，负责推进BridgeBio的总体战略，确定和投资新技术，并负责业务开发和运营。在担任该职位之前，他曾担任BridgeBio资产收购、战略和运营高级副总裁两年，负责业务发展、战略和运营。亨德森博士于2016年4月加入BridgeBio，担任资产收购、战略和运营副总裁。亨德森博士还曾担任BridgeBio多家子公司的首席执行官。在加入BridgeBio之前，亨德森博士于2015年1月至2016年4月在全球管理咨询公司麦肯锡工作，在此之前，他于2011年8月与他人共同创立了生物技术公司PellePharm，Inc.。亨德森博士自2021年2月起担任专注于医疗保健行业的特殊目的收购公司ARYA科学并购公司IV（纳斯达克：ARYD）的董事会成员，自2023年6月起担任生物技术公司Aeglea BioTherapeutics，Inc.（纳斯达克：AGLE）的董事会成员。亨德森博士在哈佛大学获得了全球健康学士学位，在斯坦福大学获得了医学博士学位。
Michael Henderson,has served as a member of Apogee Therapeutics, Inc. Board since June 2023, as a member of the board of managers of Apogee Therapeutics, LLC since 2022 and as Apogee Therapeutics, Inc. Chief Executive Officer since September 2022. Dr. Henderson is an experienced biotechnology executive with expertise in business leadership, drug development, and commercial strategy. He has overseen the creation of multiple companies, launched a significant number of drug development programs, and led teams to two FDA approvals, to date. Prior to joining Apogee, Dr. Henderson served as Chief Business Officer of BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company, from January 2020 to September 2022, where he was responsible for furthering the overarching strategy of BridgeBio, identifying and investing in new technologies and running business development and operations. Prior to holding that position, he spent two years serving as BridgeBio's Senior Vice President, Asset Acquisition, Strategy and Operations, where he was responsible for business development, strategy and operations. Dr. Henderson joined BridgeBio as Vice President of Asset Acquisition, Strategy and Operations in April 2016. Dr. Henderson also served as the Chief Executive Officer of a number of BridgeBio's subsidiaries. Prior to BridgeBio, Dr. Henderson worked at McKinsey & Company, a global management consulting firm, from January 2015 to April 2016 and prior to that, he co-founded PellePharm, Inc., a biotechnology company, in August 2011. Dr. Henderson has served on the board of directors of ARYA Sciences Acquisition Corp IV (Nasdaq: ARYD), a special purpose acquisition company focused on the healthcare industry, since February 2021 and Aeglea BioTherapeutics, Inc. (Nasdaq: AGLE), a biotechnology company, since June 2023. Dr. Henderson received his B.A. in global health from Harvard University and his M.D. from Stanford University.- Michael Henderson，自2023年6月起担任Apogee Therapeutics，Inc.董事会成员，自2022年起担任Apogee Therapeutics，LLC管理委员会成员，自2022年9月起担任Apogee Therapeutics，Inc.首席执行官。亨德森博士是一位经验丰富的生物技术高管，在商业领导、药物开发和商业战略方面具有专长。迄今为止，他领导了多家公司的创建，启动了大量的药物开发项目，并带领团队获得了两项FDA的批准。在加入Apogee之前，Henderson博士于2020年1月至2022年9月担任处于商业化阶段的生物制药公司BridgeBio Pharma（纳斯达克：BBIO）的首席商务官，负责推进BridgeBio的总体战略，确定和投资新技术，并负责业务开发和运营。在担任该职位之前，他曾担任BridgeBio资产收购、战略和运营高级副总裁两年，负责业务发展、战略和运营。亨德森博士于2016年4月加入BridgeBio，担任资产收购、战略和运营副总裁。亨德森博士还曾担任BridgeBio多家子公司的首席执行官。在加入BridgeBio之前，亨德森博士于2015年1月至2016年4月在全球管理咨询公司麦肯锡工作，在此之前，他于2011年8月与他人共同创立了生物技术公司PellePharm，Inc.。亨德森博士自2021年2月起担任专注于医疗保健行业的特殊目的收购公司ARYA科学并购公司IV（纳斯达克：ARYD）的董事会成员，自2023年6月起担任生物技术公司Aeglea BioTherapeutics，Inc.（纳斯达克：AGLE）的董事会成员。亨德森博士在哈佛大学获得了全球健康学士学位，在斯坦福大学获得了医学博士学位。
- Michael Henderson,has served as a member of Apogee Therapeutics, Inc. Board since June 2023, as a member of the board of managers of Apogee Therapeutics, LLC since 2022 and as Apogee Therapeutics, Inc. Chief Executive Officer since September 2022. Dr. Henderson is an experienced biotechnology executive with expertise in business leadership, drug development, and commercial strategy. He has overseen the creation of multiple companies, launched a significant number of drug development programs, and led teams to two FDA approvals, to date. Prior to joining Apogee, Dr. Henderson served as Chief Business Officer of BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company, from January 2020 to September 2022, where he was responsible for furthering the overarching strategy of BridgeBio, identifying and investing in new technologies and running business development and operations. Prior to holding that position, he spent two years serving as BridgeBio's Senior Vice President, Asset Acquisition, Strategy and Operations, where he was responsible for business development, strategy and operations. Dr. Henderson joined BridgeBio as Vice President of Asset Acquisition, Strategy and Operations in April 2016. Dr. Henderson also served as the Chief Executive Officer of a number of BridgeBio's subsidiaries. Prior to BridgeBio, Dr. Henderson worked at McKinsey & Company, a global management consulting firm, from January 2015 to April 2016 and prior to that, he co-founded PellePharm, Inc., a biotechnology company, in August 2011. Dr. Henderson has served on the board of directors of ARYA Sciences Acquisition Corp IV (Nasdaq: ARYD), a special purpose acquisition company focused on the healthcare industry, since February 2021 and Aeglea BioTherapeutics, Inc. (Nasdaq: AGLE), a biotechnology company, since June 2023. Dr. Henderson received his B.A. in global health from Harvard University and his M.D. from Stanford University.